Select Page

WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches of fiduciary duties and other violations of law related to Prevail’s agreement to be acquired by Eli Lilly and Company (NYSE: LLY).   Under the terms of the agreement, Prevail’s shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.